RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mereo BioPharma Group Stock

Mereo BioPharma Group Stocks 2024

Mereo BioPharma Group Stocks

659.45 M

Ticker

MREO

ISIN

US5894921072

WKN

A2PEYJ

In 2024, Mereo BioPharma Group had 659.45 M outstanding stocks, a 0% change from the 659.45 M stocks in the previous year.

The Mereo BioPharma Group Stocks history

YEARNUMBER OF STOCKS (undefined GBP)
2029e659.45
2028e659.45
2027e659.45
2026e659.45
2025e659.45
2024e659.45
2023659.45
2022603.2
2021527.82
2020338.95
201989.42
201871.14
201769.01
201644.79
201564.34

Mereo BioPharma Group shares outstanding

The number of shares was Mereo BioPharma Group in 2023 — This indicates how many shares 659.454 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Mereo BioPharma Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Mereo BioPharma Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Mereo BioPharma Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mereo BioPharma Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Mereo BioPharma Group Aktienanalyse

What does Mereo BioPharma Group do?

Mereo BioPharma Group plc was founded in 2015 and is based in Reading, UK. The company is a pharmaceutical industry company that focuses on the development of treatments for rare and unmet medical needs. Mereo BioPharma is an emerging biotechnology company that discovers, develops, and markets innovative drugs. The company employs an experienced team of scientists and researchers dedicated to developing therapies that address unmet medical needs. Mereo BioPharma specializes in four areas of interest in which it is actively working on new developments: oncology, rare diseases, gynecological and endocrine disorders, and respiratory diseases. The company aims to advance innovative drug developments that focus on rare and unmet medical needs. These typically have received little attention from larger, established pharmaceutical companies. However, they represent a tremendous opportunity to identify and successfully bring to market high-quality and effective drugs. Mereo BioPharma is listed on the London Stock Exchange (AIM) and has a strong financial foundation. Mereo is preparing to launch two new products - Alvelestat and Setrusumab - for the treatment of respiratory diseases and osteogenesis imperfecta. Mereo's business model is based on a multi-stage development pipeline: from the discovery of potential drug candidates to clinical trials and marketing. The company works closely with established partners to pool the necessary resources and expertise required for the development and successful commercialization of an outstanding product. Alvelestat is a unique therapy specifically developed for patients with alpha-1 antitrypsin deficiency. The drug is used to treat lung and liver diseases often associated with this condition. It is currently in Phase II of clinical development. Setrusumab is an innovative product for the treatment of osteogenesis imperfecta, a rare bone disorder often diagnosed in early childhood. The drug is currently in Phase III of the approval process. The company's future plans include expanding its pipeline to create treatment options for patients worldwide. Mereo utilizes advanced technologies and modern methods to foster research, development, and clinical studies and ensure the success of its products in the market. Mereo BioPharma Group plc is a young, exciting company specializing in the development of drugs for the treatment of rare and unmet medical needs. The company focuses on three strategic priorities: research and development of innovative drugs, collaboration with strong partners, and marketing and distribution of its products. Mereo has a strong financial foundation and is committed to expanding its pipeline to meet new patient needs. Mereo BioPharma Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Mereo BioPharma Group's Shares Outstanding

Mereo BioPharma Group's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Mereo BioPharma Group’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Mereo BioPharma Group’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Mereo BioPharma Group’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Mereo BioPharma Group stock

How many stocks are there of Mereo BioPharma Group?

The current number of stocks of Mereo BioPharma Group is 659.45 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Mereo BioPharma Group are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Mereo BioPharma Group evolved in recent years?

The number of shares of Mereo BioPharma Group has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Mereo BioPharma Group as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Mereo BioPharma Group?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Mereo BioPharma Group pay?

Over the past 12 months, Mereo BioPharma Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mereo BioPharma Group is expected to pay a dividend of 0 GBP.

What is the dividend yield of Mereo BioPharma Group?

The current dividend yield of Mereo BioPharma Group is .

When does Mereo BioPharma Group pay dividends?

Mereo BioPharma Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mereo BioPharma Group?

Mereo BioPharma Group paid dividends every year for the past 0 years.

What is the dividend of Mereo BioPharma Group?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mereo BioPharma Group located?

Mereo BioPharma Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mereo BioPharma Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mereo BioPharma Group from 9/20/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did Mereo BioPharma Group pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Mereo BioPharma Group in the year 2023?

In the year 2023, Mereo BioPharma Group distributed 0 GBP as dividends.

In which currency does Mereo BioPharma Group pay out the dividend?

The dividends of Mereo BioPharma Group are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mereo BioPharma Group

Our stock analysis for Mereo BioPharma Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mereo BioPharma Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.